A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
Vaccine
; 39(43): 6398-6406, 2021 10 15.
Article
de En
| MEDLINE
| ID: mdl-34593270
ABSTRACT
BACKGROUND:
We previously demonstrated that RTS,S/AS01B and RTS,S/AS01E vaccination regimens including at least one delayed fractional dose can protect against Plasmodium falciparum malaria in a controlled human malaria infection (CHMI) model, and showed inferiority of a two-dose versus three-dose regimen. In this follow-on trial, we evaluated whether fractional booster vaccination extended or induced protection in previously protected (P-Fx) or non-protected (NP-Fx) participants.METHODS:
49 participants (P-Fx 25; NP-Fx 24) received a fractional (1/5th dose-volume) RTS,S/AS01E booster 12 months post-primary regimen. They underwent P. falciparum CHMI three weeks later and were then followed for six months for safety and immunogenicity.RESULTS:
Overall vaccine efficacy against re-challenge was 53% (95% CI 37-65%), and similar for P-Fx (52% [95% CI 28-68%]) and NP-Fx (54% [95% CI 29-70%]). Efficacy appeared unaffected by primary regimen or previous protection status. Anti-CS (repeat region) antibody geometric mean concentrations (GMCs) increased post-booster vaccination. GMCs were maintained over time in primary three-dose groups but declined in the two-dose group. Protection after re-challenge was associated with higher anti-CS antibody responses. The booster was well-tolerated.CONCLUSIONS:
A fractional RTS,S/AS01E booster given one year after completion of a primary two- or three-dose RTS,S/AS01 delayed fractional dose regimen can extend or induce protection against CHMI. CLINICAL TRIAL REGISTRATION NCT03824236. linked to this article can be found on the Research Data as well as Figshare https//figshare.com/s/ee025150f9d1ac739361.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Paludisme à Plasmodium falciparum
/
Vaccins contre le paludisme
/
Paludisme
Type d'étude:
Clinical_trials
Limites:
Humans
Langue:
En
Journal:
Vaccine
Année:
2021
Type de document:
Article